- Home
- RPAY vs SLN Comparison
RPAY vs SLN Comparison
Compare RPAY & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPAY
- SLN
- Stock Information
- Founded
- RPAY 2006
- SLN 1994
- Country
- RPAY United States
- SLN United Kingdom
- Employees
- RPAY N/A
- SLN N/A
- Industry
- RPAY Business Services
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- RPAY Consumer Discretionary
- SLN Health Care
- Exchange
- RPAY Nasdaq
- SLN Nasdaq
- Market Cap
- RPAY 894.8M
- SLN 928.5M
- IPO Year
- RPAY N/A
- SLN N/A
- Fundamental
- Price
- RPAY $8.02
- SLN $18.65
- Analyst Decision
- RPAY Buy
- SLN Strong Buy
- Analyst Count
- RPAY 8
- SLN 4
- Target Price
- RPAY $11.57
- SLN $61.50
- AVG Volume (30 Days)
- RPAY 1.4M
- SLN 246.6K
- Earning Date
- RPAY 08-08-2024
- SLN 08-15-2024
- Dividend Yield
- RPAY N/A
- SLN N/A
- EPS Growth
- RPAY N/A
- SLN N/A
- EPS
- RPAY N/A
- SLN N/A
- Revenue
- RPAY $305,933,000.00
- SLN $22,623,125.00
- Revenue This Year
- RPAY $9.25
- SLN N/A
- Revenue Next Year
- RPAY $7.86
- SLN $104.98
- P/E Ratio
- RPAY N/A
- SLN N/A
- Revenue Growth
- RPAY 5.30
- SLN N/A
- 52 Week Low
- RPAY $5.63
- SLN $6.15
- 52 Week High
- RPAY $11.27
- SLN $27.72
- Technical
- Relative Strength Index (RSI)
- RPAY 35.84
- SLN 53.96
- Support Level
- RPAY $8.27
- SLN $17.26
- Resistance Level
- RPAY $8.61
- SLN $20.12
- Average True Range (ATR)
- RPAY 0.28
- SLN 1.11
- MACD
- RPAY 0.03
- SLN 0.33
- Stochastic Oscillator
- RPAY 0.00
- SLN 65.80
About RPAY Repay Holdings Corporation
Repay Holdings Corp is engaged in providing integrated payment processing solutions to verticals that have transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segment, Consumer Payment and Business Payments.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.